Table 2. . Updates in neoadjuvant therapy for esophageal, gastric and gastroesophageal junction cancer.
Study | Trial | Cancer type | Eligibility | Phase | Number of patients (n) | Timing | Intervention | End point | Ref. |
---|---|---|---|---|---|---|---|---|---|
Shapiro et al. | CROSS | Esophageal/GEJ | cT12N1M0 or T2–3N0–1M0 | III | 368 | Neoadjuvant | CP + surgery vs surgery alone | Median OS 48.6 vs 24.0 mo (p = 0.003) | [6] |
Goodman et al. | CALGB80803 | Esophageal/GEJ | cT3–4 or N+ | II | 257 | Adjuvant | FOLFOX-6 or CP, PET nonresponders crossed over to alternate chemotherapy | pCR for PET-nonresponders pCR 15.6% | [9] |
Al-Batran et al. | FLOT4-AIO | Gastric/GEJ | cT2+ and/or cN+ | II/III | 300 | Adjuvant | FLOT vs ECF/ECX | 3y OS 57 vs 48% | [98] |
CP: Chemotherapy; ECF: Epirubicin, cisplatin, fluorouracil; ECX: Epirubicin, cisplatin, capecitabine; FLOT: Fluorouracil, leucovorin, oxaliplatin, docetaxel; GEJ: Gastroesophageal junction; mo: Month; OS: Overall survival; pCR: Pathologic complete response rate; PET: Positron emission technology.